ACIU NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

AC Immune Ltd · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 2.19 USD
-1.8% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -21.6% below the Trend Line and sits at 8.1% of its 52-week range. The latest completed week returned -1.8%, after a -12.7% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers. Options positioning is bullish with 41/100 conviction, while the latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 2d.

Setup score 18 out of 100
Latest Close 2.19 USD 31 Jul 2026
1W Return -1.8% latest completed week
4W Return -12.7% short-term follow-through
12W Return -23.4% quarterly tape
Trend Breadth 44.2% 23 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -1.8% Latest completed week; four-week move -12.7%. Indicator stack 24/18 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 41/100 conviction; expected move 33.8%. News sentiment 53/100 48 relevant articles in the latest sentiment read. Event risk 2d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -21.6% below the Trend Line and sits at 8.1% of its 52-week range. The latest completed week returned -1.8%, after a -12.7% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0112-week average 0.12

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.01Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -12.7% over four weeks, -23.4% over 12 weeks, and 3.3% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-1.8%
4W-12.7%
12W-23.4%
26W-31.3%
52W3.3%
Active trend streak0 weeks
Active weeks in one year23
Trend breadth44.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.57Latest activity-pressure read.
Pressure change-47.3%Four-week change in activity pressure.
Leadership-29.62Latest relative-leadership reading.
RS change-28.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 79% Model confidence 76%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength5/100Blend of value, momentum, and quality. Underlying universe rank 96; rank 1 is best.
Value18/100Relative valuation strength. Underlying universe rank 83; rank 1 is best.
Quality11/100Profitability and accounting quality. Underlying universe rank 90; rank 1 is best.
Momentum24/100Medium-term price momentum. Underlying universe rank 77; rank 1 is best.
Growth10/100Revenue and earnings growth. Underlying universe rank 91; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
61.3x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-30.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
100.0%
Gross profit retained from each unit of revenue.
Operating margin
-1785.8%
Operating profit retained from revenue.
Free-cash-flow margin
-1763.6%
Free cash flow generated from revenue.
Return on invested capital
-297.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-86.9%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.0%
Net share repurchases relative to market value.
Shareholder yield
-0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

ACIU shows bullish options pressure with a 41/100 conviction score, put-call volume ratio of 0.24, expected move of 33.8%, and Sharemaestro trend signal inactive.

Conviction41/100
Expected move33.8%
Put/call volume0.24
Pressure71
Speculation7
Volatility96
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 48 relevant articles.

10 positive · 34 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings2dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move33.8%Nearest-chain priced movement where available.
52-week drawdown-45.2%Distance below the 52-week high.
13-week volatility5.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2616 weeks finished lower.
Best week+18.8%Week of 10 Apr.
Worst week-15.7%Week of 20 Feb.
Latest week-1.8%Week of 31 Jul.

Shape of recent returns

Strong gains5
Modest gains5
Flat weeks0
Modest losses4
Sharp losses12
Recent vol5.5%13-week weekly-return volatility.
Base vol9.7%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew7.7% / -6.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape21/100

Trend, activity pressure, participation, and risk combine to a 21/100 tape read.

 Indicator analysis9/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.01; No reversal markers Factors13/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 68; Small Cap Core rank 88 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options42/100

ACIU shows bullish options pressure with a 41/100 conviction score, put-call volume ratio of 0.24, expected move of 33.8%, and Sharemaestro trend signal inactive.

Bullish · Call-side pressure · Expected move 33.8% Sentiment53/100

Weighted news tone is neutral across 48 relevant articles.

AC Immune SA Revenue Breakdown – HAM:IMR Insiders50/100

No recent insider transaction evidence is stored.

 Earnings2d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20262.19 USD-1.8%2.79 USD2.92 USD-1.57-29.62771.0KOff
24 Jul 20262.23 USD1.4%2.83 USD2.93 USD-1.32-28.141.0MOff
17 Jul 20262.20 USD-7.9%2.86 USD2.93 USD-1.12-30.551.1MOff
10 Jul 20262.39 USD-4.8%2.89 USD2.94 USD-1.09-27.861.1MOff
3 Jul 20262.51 USD-2.0%2.92 USD2.94 USD-1.07-22.991.8MOff
26 Jun 20262.56 USD6.7%2.92 USD2.94 USD-1.25-20.851.4MOff
19 Jun 20262.40 USD3.9%2.94 USD2.95 USD-1.14-29.15663.3KOff
12 Jun 20262.31 USD2.7%2.96 USD2.94 USD-0.84-30.092.1MOff
5 Jun 20262.25 USD-15.4%2.99 USD2.94 USD-0.64-30.481.8MOff
29 May 20262.66 USD-6.0%3.03 USD2.94 USD-0.42-21.73976.3KOff
22 May 20262.83 USD1.4%3.05 USD2.94 USD-0.45-14.22900.2KOff
15 May 20262.79 USD-2.4%3.06 USD2.94 USD-0.59-14.181.7MOff
8 May 20262.86 USD-4.0%3.07 USD2.93 USD-0.64-12.071.4MOff
1 May 20262.98 USD4.9%3.09 USD2.93 USD-0.54-3.121.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.